Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3

Antiviral Therapy

Volumn 13, Issue SUPPL. 1, 2008, Pages 17-22

  Berg, Thomas ^a   Carosi, Giampiero ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 42149111628     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl 1:9-16.
2. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960.
3. Shiffman ML, Suter FS, Bacon BR, et al. Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124-134.
4. Shiffman M, Pappas S, Bacon B, et al. Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with peginterferon alpha-2a plus ribavirin: findings from ACCELERATE. Hepatology 2006; 44 Suppl 1:316A-317A.
5. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:225-230.
6. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
7. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon-alphala and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
8. Dalgard O, Bjoro K, Helium KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265.
9. Mangia A, Santoro R, Minerva N, et al. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
10. von-Wagner M, Huber M, Berg T, et al. Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
11. Yu ML, Dai CY, Huang JF, et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56:553-559.
12. Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antivir Ther 2008; 13 Suppl 1:23-30.
13. Ferenci P, Brunner H, Laferl H, et al. Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus): interim results of a randomized controlled trial. J Hepatol 2006; 44 Suppl 2:S37.
14. Shiffman M, Pappas S, Greenbloom S, et al. Effect of drug exposure on sustained virological response (SVR) in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks. Hepatology 2006; 44 Suppl 1:317A.
15. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
16. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
17. Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 2007; 46 Suppl 1:S6.